Bulk Pharmaceutical API Sources for CHLORHEXIDINE GLUCONATE

Bulk Pharmaceutical API Sources for CHLORHEXIDINE GLUCONATE

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		9552081
ISpharm		I06-2074
ChemMol		49411785
AKos Consulting & Solutions		AKOS015896303
AK Scientific, Inc. (AKSCI)		M166
Chembase.cn		132286

API Sources for Chlorhexidine Gluconate

Last updated: February 22, 2026

What are the primary bulk suppliers for chlorhexidine gluconate API?

Multiple manufacturers globally produce chlorhexidine gluconate API, primarily based in Asia, Europe, and North America. The market features a mix of large-scale pharmaceutical API producers and smaller specialty chemical companies.

Who are the leading suppliers of chlorhexidine gluconate API?

Company	Country	Production Capacity	Certification & Standards	Notes
Jiangsu Yige Pharmaceutical	China	~50 MT/year	ISO 9001, GMP	Largest volume supplier, supplies global markets
Fagron (Luxembourg)	Luxembourg	Data unavailable	GMP, ISO 9001	Focus on pharmaceutical raw materials, bioequivalence studies
Lake Cities Pharmaceutical	India	~20 MT/year	WHO-GMP, ISO 9001	Growing export presence, competitive pricing
I.C.P. Pharma	China	~30 MT/year	GMP, ISO 9001	Established exporter, FDA approved facilities
Puracap (India)	India	Data unavailable	GMP, ISO 9001	Small batch, specialty API producer

How do different sources compare in production, quality, and compliance?

• Production Capacity: China and India dominate with capacities exceeding 20 MT/year. Europe and North America generally do not produce API at scale but may supply formulations.
• Quality Standards: GMP certification is standard among leading suppliers. ISO 9001 certifications support quality management.
• Regulatory Approvals: Suppliers like Lake Cities Pharma and I.C.P. Pharma meet WHO-GMP and FDA standards, facilitating global distribution.
• Pricing: Lower manufacturing costs in Asia enable more competitive pricing, though quality standards vary. European and American suppliers often have higher costs but strict compliance.

Are there regional or certification barriers impacting API sourcing?

• Regional barriers: Some regulators restrict imports from countries with less stringent regulations. European and US approvals often favor sources from GMP-certified producers.
• Certification barriers: Companies without GMP or equivalent certifications face limited acceptance in strict markets. Validations from multiple regulatory authorities enhance market access.

What are the trends affecting API sourcing for chlorhexidine gluconate?

• Shift towards Asia: Increased capacity and cost advantages drive supply chain shifts to Chinese and Indian manufacturers.
• Quality improvements: Suppliers invest in GMP compliance and robust quality assurance, increasing trustworthiness.
• Supply chain resilience: Diversification from single-source regions minimizes risk amid geopolitical and logistical disruptions.

Additional notes

• The API market for chlorhexidine gluconate remains concentrated with fewer high-volume producers.
• Validation of API sourcing involves certificates of analysis, GMP certificates, and adherence to regional regulations.

---

Key Takeaways

• China and India are the dominant API sources for chlorhexidine gluconate, offering large capacities and competitive prices.
• European and North American suppliers are generally smaller but emphasize higher compliance standards.
• Regulatory considerations influence API sourcing decisions; GMP certification is crucial.
• Supply chain disruptions and geopolitical issues prioritize diversification.
• Quality assurance and certification standards impact acceptance and application scope.

FAQs

1. How does API quality impact downstream product safety?
API quality directly affects the safety and efficacy of final pharmaceutical products. Standards such as GMP ensure consistent quality, reducing variability and risk.

2. What certifications are most valued for chlorhexidine gluconate API?
GMP certification is essential for market acceptance, especially in regulated markets like the US and EU. ISO 9001 supports quality management but does not replace GMP.

3. Are there local API sources for chlorhexidine gluconate in North America?
Limited production exists domestically. Most North American companies source from Asian manufacturers due to higher production costs and limited capacity locally.

4. What are the risks of sourcing API from Asian suppliers?
Risks include regulatory differences, quality variations, and supply chain disruptions. Certification and audit processes mitigate these risks.

5. Can API sourced from China or India be used directly in pharmaceutical manufacturing?
Yes, if the supplier holds valid GMP certifications and provides compliant documentation. Qualification and validation processes are necessary before use.

---

References

1. U.S. Food and Drug Administration. (2022). Drug Establishments Current Registration Site. https://www.fda.gov
2. European Medicines Agency. (2021). Guidelines on Good Manufacturing Practice. https://www.ema.europa.eu
3. World Health Organization. (2022). Prequalification of Medicines Programme. https://www.who.int
4. MarketsandMarkets. (2020). Pharmaceutical API Market by Source, End-User, and Region. https://www.marketsandmarkets.com
5. Chinese Pharmacopoeia. (2021). Pharmacopoeial Standards. National Medical Products Administration.